Human platelet lysate is derived from platelets of healthy human blood donors through several steps involving freezing and thawing. It finds wide application in cell culture media as it supports cell growth and proliferation. It is commonly used as an alternative to fetal bovine serum for culturing mesenchymal stem cells, endothelial cells or fibroblasts. It aids cell growth without the risk of triggering an immune response, making it safer than animal-derived supplements.
The global Human Platelet Lysate Market is estimated to be valued at Us$ 61.06 Bn in 2023 and is expected to exhibit a CAGR Of 9.4% over the forecast period 2024 To 2031, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
One of the key drivers for the growth of the human platelet lysate market is the rising global prevalence of chronic diseases. Chronic diseases such as cancer, cardiovascular diseases and diabetes necessitate the need for adopting regenerative medicine approaches. Human platelet lysate plays a pivotal role in cell-based therapies and tissue engineering applications used in treating chronic diseases. Moreover, human platelet lysate minimizes the risk of transplant rejection, immunogenic response and disease transmission associated with use of animal or human-derived supplements in culture media, thus propelling its demand. Additionally, growing awareness about benefits of platelet lysate over fetal bovine serum and rapid advancement in cell-based research further accelerates the market growth.
SWOT Analysis
Strength: Human platelet lysate is considered the best replacement for fetal bovine serum to grow stem cells. It is safer as there is no risk of disease transmission. Production of platelet lysate is also simpler and more cost effective than fetal bovine serum. Large pharmaceutical companies are developing standardized platelet lysate products which will help increase its adoption in cell therapy.
Weakness: Quality and safety assurance of platelet lysate remains a concern due to lack of standardized production processes. Differences in platelet lysate produced from different blood banks leads to batch to batch variability issues. Development of cross-reactive antibodies against lymphocytes during autologous use of platelet lysate is also a limitation.
Opportunity: Increasing stem cell research and regenerative medicine applications are driving the demand for platelet lysate. It is expected to replace fetal bovine serum completely in coming years due to safety and standardization advancements. Developing economies like China, India provide huge market potential with their large population and improving healthcare investments.
Threats: Stringent regulatory approval process and high costs associated with clinical trials delays market growth. Limited manufacturing capacities of blood banks also restricts large scale commercial production of platelet lysate. Intense competition from other serum-free media and xenofree cell culture products poses pricing challenges.
Key Takeaways
The Global Human Platelet Lysate Market Demand is expected to witness high growth over the forecast period of 2024 to 2031.
Regional analysis:
The North American region currently dominates the global market owing to rising stem cell research activities backed by strong government funding. Europe is another major regional market for platelet lysate with significant stem cell related research conducted in countries like Germany and UK. The Asia Pacific region is expected to offer lucrative growth opportunities with China and India emerging as global manufacturing hubs for cell therapies.
Key players operating in the Human Platelet Lysate market are Air Methods Corporation, Deccan Charters, Scandinavian Air Ambulance, Air Ambulance Specialists, Air Charter Service, Envision Healthcare Companies, Falck Danmark A/S, AMR Air Ambulance, AirMed International, Express Aviation Services, ALPHASTAR. These companies are focused on developing innovative production technologies and collaborating with research institutes to increase platelet lysate adoption in clinical applications.
Get More Insights On This Topic :
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek